Linical Co Ltd
TSE:2183

Watchlist Manager
Linical Co Ltd Logo
Linical Co Ltd
TSE:2183
Watchlist
Price: 330 JPY Market Closed
Market Cap: 7.5B JPY
Have any thoughts about
Linical Co Ltd?
Write Note
Linical Co Ltd
/
Balance Sheet
/
Accounts Receivables

Linical Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Linical Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Linical Co Ltd
TSE:2183
Accounts Receivables
¥2.9B
CAGR 3-Years
2%
CAGR 5-Years
12%
CAGR 10-Years
16%
CMIC Holdings Co Ltd
TSE:2309
Accounts Receivables
¥16.9B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
8%
C
Chiome Bioscience Inc
TSE:4583
Accounts Receivables
¥60.9m
CAGR 3-Years
12%
CAGR 5-Years
-9%
CAGR 10-Years
7%
Medinet Co Ltd
TSE:2370
Accounts Receivables
¥227.8m
CAGR 3-Years
1%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
CellSource Co Ltd
TSE:4880
Accounts Receivables
¥361.5m
CAGR 3-Years
17%
CAGR 5-Years
21%
CAGR 10-Years
N/A
WDB coco Co Ltd
TSE:7079
Accounts Receivables
¥1.3B
CAGR 3-Years
27%
CAGR 5-Years
24%
CAGR 10-Years
N/A
No Stocks Found

Linical Co Ltd
Glance View

Market Cap
7.5B JPY
Industry
Life Sciences Tools & Services

Linical Co., Ltd. engages in pharmaceutical contract research projects providing consulting, monitoring, and quality control services to pharmaceutical companies. The company is headquartered in Osaka, Osaka-Fu and currently employs 845 full-time employees. The company went IPO on 2008-10-27. The firm operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Intrinsic Value
1 016.58 JPY
Undervaluation 68%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Linical Co Ltd's Accounts Receivables?
Accounts Receivables
2.9B JPY

Based on the financial report for Sep 30, 2024, Linical Co Ltd's Accounts Receivables amounts to 2.9B JPY.

What is Linical Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
16%

Over the last year, the Accounts Receivables growth was -16%. The average annual Accounts Receivables growth rates for Linical Co Ltd have been 2% over the past three years , 12% over the past five years , and 16% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.